FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer (Q80092106)
Jump to navigation
Jump to search
scientific article published on 01 March 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer |
scientific article published on 01 March 2007 |
Statements
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer (English)
Martin H Cohen
Joe Gootenberg
Patricia Keegan